| 董丽娜,王静萱.PD-1/PD-L1抑制剂在晚期尿路上皮癌中的研究进展[J].肿瘤学杂志,2018,24(2):140-145. |
| PD-1/PD-L1抑制剂在晚期尿路上皮癌中的研究进展 |
| Research Progress of PD-1/PD-L1 Inhibitor Immunotherapy in Advanced Urothelial Cancer |
| 投稿时间：2017-05-02 |
| DOI：10.11735/j.issn.1671-170X.2018.02.B012 |
|
 |
| 中文关键词: 尿路上皮癌 免疫治疗 程序性死亡受体1 程序性死亡配体1 |
| 英文关键词:urothelial cancer immunotherapy programmed death 1 programmed death ligand 1 |
| 基金项目:国家自然科学基金资助项目（81472490） |
|
| 摘要点击次数: 2159 |
| 全文下载次数: 406 |
| 中文摘要: |
| 摘 要：含顺铂方案的化疗是晚期尿路上皮癌的一线治疗方式，不耐受顺铂化疗的及一线标准化疗后发生疾病进展的患者可选择的有效治疗有限，平均生存期约5~10个月。程序性死亡受体1（programmed death 1，PD-1）/程序性死亡配体1（programmed death ligand 1，PD-L1）抑制剂在大型临床试验中显示出持久的抗肿瘤效应和可耐受的安全性，为改善晚期尿路上皮癌患者预后带来了希望。PD-1抑制剂Pembrolizumab是第一个获得美国食品药品管理局（Food and Drug Administration，FDA）批准的治疗晚期尿路上皮癌的一线免疫治疗药物。2种PD-1抑制剂Pembrolizumab和Nivolumab，3种PD-L1抑制剂Atezolizumab、Durvalumab和Avelumab，先后获得美国FDA批准作为含铂方案化疗进展的晚期尿路上皮癌患者的二线治疗药物。全文就PD-1/PD-L1抑制剂在晚期尿路上皮癌中的研究进展作一综述。 |
| 英文摘要: |
| Abstract：First-line standard care for patients with advanced urothelial cancer is platinum-containing chemotherapy. Alternative effective therapy regimens are limited in platinum-intolerant patients or patients with disease progression during or after platinum-containing chemotherapy，whose survival time averages 5～10 months. Programmed death 1(PD-1) / Programmed death ligand 1(PD-L1) inhibitor has demonstrated durable anti-tumor efficacy and tolerable safety in clinical trials，bringing hope of better prognosis to patients having advanced urothelial cancer. Pembrolizumab，a PD-1-blocked antibody，has become the first immunotherapy medicine approved by Food and Drug Administration(FDA) for first-line advanced urothelial cancer therapy. FDA has also approved two PD-1-blocked inhibitors(Pembrolizumab and Nivolumab) and three PD-L1-blocked inhibitors(Atezolizumab，Durvalumab，and Avelumab) as second-line treatment for patients with advanced urothelial cancer. Research progress of PD-1/PD-L1 inhibitor immunotherapy in advanced urothelial cancer was summarized in this article. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |